ANN ARBOR – In the heat of looking for funding from traditional sources such as Venture Capitalists, start-ups often overlook opportunities for additional funds from Patient Advocacy Groups. On Nov. 5, Ann Arbor Spark will explore maximizing start-up opportunities with these foundations.
Foundations certainly serve as a potential source for seed grants and clinical trial support, especially for companies whose technology targets a specific disease. However, patient advocacy foundations can also provide other resources, including critical access to experts and databases of patients for clinical trials.
What drives the investing decisions of foundations?
How can entrepreneurs better define their goals in approaching foundations in order to maximize the opportunity for support at crucial time points of growth, such as early stage-funding or during an exit?
What does “success” look like for both parties?
Steps to evolve the relationship between the parties to ensure continued commitment?
Speakers include Bill Cadwallder, Senior Commercialization Officer, PATH, and Bruce Markham, PhD, President & CEO, Diapin Therapeutics. Networking begins at 5 pm and the program at 6.
The program will be held at Ann Arbor SPARK Central, 330 E. Liberty, Lower Level, Ann Arbor, MI 48104
BioArbor hosts educational networking events for the life sciences industry in the greater Ann Arbor area. BioArbor’s focus is on technology commercialization, financing strategies, business development, regulatory affairs, and marketing. Each monthly meeting features a networking session and an invited speaker, followed by a Q&A period. Invited speakers share experience on topics such as drug discovery and development, medical devices, diagnostics, and tools. BioArbor events are open to the public and are especially suited for those interested in starting or growing life science businesses.
